It's pretty remarkable just how quickly a hepatitis C (HCV) drug candidate can go from hero to villain in today's market. Investors cheered Gilead's (GILD) bold (and expensive) bid for Pharmasset ... until some concerns about the efficacy of lead drug GS-7977 popped up. Then there was Bristol-Myers Squibb (BMY) making its bold play for Inhibitex, only to see serious safety worries emerge on the key asset (now known as BMS-094).
Now it's the turn of Idenix (IDIX).
In a case of what looks to me like guilt by association, the FDA has
put lead drug IDX184 on a partial clinical hold due to worries about
Please click here for more:
Idenix And The High-Stakes Ping-Pong Of Hep C Treatments